{"analyses":[{"ciNumSides":"TWO_SIDED","groupIds":["OG000","OG004"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.217","pValueComment":"P-value is for Physician's Assessment of DA - Week 12. A priori p-value significance threshold: 2-sided ≤0.10.","statisticalMethod":"ANCOVA"},{"ciNumSides":"TWO_SIDED","groupIds":["OG001","OG004"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.092","pValueComment":"P-value is for Physician's Assessment of DA - Week 12. A priori p-value significance threshold: 2-sided ≤0.10.","statisticalMethod":"ANCOVA"},{"ciNumSides":"TWO_SIDED","groupIds":["OG002","OG004"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"P-value is for Physician's Assessment of DA - Week 12. A priori p-value significance threshold: 2-sided ≤0.10.","statisticalMethod":"ANCOVA"},{"ciNumSides":"TWO_SIDED","groupIds":["OG003","OG004"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"P-value is for Physician's Assessment of DA - Week 12. A priori p-value significance threshold: 2-sided ≤0.10.","statisticalMethod":"ANCOVA"},{"ciNumSides":"TWO_SIDED","groupIds":["OG000","OG004"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"P-value is for Patient's Assessment of DA - Week 12. A priori p-value significance threshold: 2-sided ≤0.10.","statisticalMethod":"ANCOVA"},{"ciNumSides":"TWO_SIDED","groupIds":["OG001","OG004"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.072","pValueComment":"P-value is for Patient's Assessment of DA - Week 12. A priori p-value significance threshold: 2-sided ≤0.10.","statisticalMethod":"ANCOVA"},{"ciNumSides":"TWO_SIDED","groupIds":["OG002","OG004"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"P-value is for Patient's Assessment of DA - Week 12. A priori p-value significance threshold: 2-sided ≤0.10.","statisticalMethod":"ANCOVA"},{"ciNumSides":"TWO_SIDED","groupIds":["OG003","OG004"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"P-value is for Patient's Assessment of DA - Week 12. A priori p-value significance threshold: 2-sided ≤0.10.","statisticalMethod":"ANCOVA"},{"ciNumSides":"TWO_SIDED","groupIds":["OG000","OG004"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"P-value is for Patient's Assessment of Pain - Week 12. A priori p-value significance threshold: 2-sided ≤0.10.","statisticalMethod":"ANCOVA"},{"ciNumSides":"TWO_SIDED","groupIds":["OG001","OG004"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.082","pValueComment":"P-value is for Patient's Assessment of Pain - Week 12. A priori p-value significance threshold: 2-sided ≤0.10.","statisticalMethod":"ANCOVA"},{"ciNumSides":"TWO_SIDED","groupIds":["OG002","OG004"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"P-value is for Patient's Assessment of Pain - Week 12. A priori p-value significance threshold: 2-sided ≤0.10.","statisticalMethod":"ANCOVA"},{"ciNumSides":"TWO_SIDED","groupIds":["OG003","OG004"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"P-value is for Patient's Assessment of Pain - Week 12. A priori p-value significance threshold: 2-sided ≤0.10.","statisticalMethod":"ANCOVA"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.49","value":"-23.9"},{"groupId":"OG001","spread":"20.81","value":"-25.0"},{"groupId":"OG002","spread":"18.75","value":"-30.4"},{"groupId":"OG003","spread":"19.49","value":"-33.5"},{"groupId":"OG004","spread":"21.40","value":"-19.0"}]}],"title":"Physician's Assessment of DA - Week 12"},{"categories":[{"measurements":[{"comment":"Participants were not dosed with 1 mg LY3009104 after Week 12, therefore mean and SD were not calculated.","groupId":"OG000","spread":"NA","value":"NA"},{"groupId":"OG001","spread":"21.13","value":"-27.8"},{"groupId":"OG002","spread":"17.72","value":"-35.5"},{"groupId":"OG003","spread":"18.73","value":"-37.8"},{"comment":"Participants were not dosed with placebo after Week 12, therefore mean and SD were not calculated.","groupId":"OG004","spread":"NA","value":"NA"}]}],"title":"Physician's Assessment of DA - Week 24"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"27.26","value":"-24.9"},{"groupId":"OG001","spread":"22.43","value":"-16.2"},{"groupId":"OG002","spread":"21.61","value":"-25.4"},{"groupId":"OG003","spread":"21.20","value":"-29.8"},{"groupId":"OG004","spread":"22.02","value":"-10.3"}]}],"title":"Patient's Assessment of DA - Week 12"},{"categories":[{"measurements":[{"comment":"Participants were not dosed with 1 mg LY3009104 after Week 12, therefore mean and SD were not calculated.","groupId":"OG000","spread":"NA","value":"NA"},{"groupId":"OG001","spread":"24.96","value":"-16.9"},{"groupId":"OG002","spread":"21.85","value":"-30.2"},{"groupId":"OG003","spread":"20.90","value":"-30.0"},{"comment":"Participants were not dosed with placebo after Week 12, therefore mean and SD were not calculated.","groupId":"OG004","spread":"NA","value":"NA"}]}],"title":"Patient's Assessment of DA - Week 24"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"27.39","value":"-22.8"},{"groupId":"OG001","spread":"17.82","value":"-14.2"},{"groupId":"OG002","spread":"19.22","value":"-25.0"},{"groupId":"OG003","spread":"20.31","value":"-25.3"},{"groupId":"OG004","spread":"22.77","value":"-8.8"}]}],"title":"Patient's Assessment of Pain - Week 12"},{"categories":[{"measurements":[{"comment":"Participants were not dosed with 1 mg LY3009104 after Week 12, therefore mean and SD were not calculated.","groupId":"OG000","spread":"NA","value":"NA"},{"groupId":"OG001","spread":"20.57","value":"-14.7"},{"groupId":"OG002","spread":"22.11","value":"-27.3"},{"groupId":"OG003","spread":"19.22","value":"-26.9"},{"comment":"Participants were not dosed with placebo after Week 12, therefore mean and SD were not calculated.","groupId":"OG004","spread":"NA","value":"NA"}]}],"title":"Patient's Assessment of Pain - Week 24"}],"denoms":[{"counts":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"52"},{"groupId":"OG002","value":"51"},{"groupId":"OG003","value":"50"},{"groupId":"OG004","value":"98"}],"units":"Participants"}],"description":"Physician's and Patient's Assessments of Disease Activity (DA) assessed using a visual analog scale (VAS) that ranged from 0 to 100 millimeters (mm), where 0 indicated no arthritis activity and 100 indicated extremely active arthritis. Patient's assessment of pain due to arthritis was also assessed using a VAS that ranged from 0 (no pain) to 100 mm (worst possible pain).","dispersionType":"Standard Deviation","groups":[{"description":"1 mg LY3009104 administered orally QD for 12 weeks in Part A.\n\nMTX was administered orally as background therapy.","id":"OG000","title":"1 mg LY3009104"},{"description":"2 mg LY3009104 administered orally QD for 24 weeks in Parts A and B.\n\nMTX was administered orally as background therapy.","id":"OG001","title":"2 mg LY3009104"},{"description":"4 mg LY3009104 administered orally QD for 24 weeks in Parts A and B.\n\nMTX was administered orally as background therapy.","id":"OG002","title":"4 mg LY3009104"},{"description":"8 mg LY3009104 administered orally QD for 24 weeks in Parts A and B.\n\nMTX was administered orally as background therapy.","id":"OG003","title":"8 mg LY3009104"},{"description":"Placebo administered orally QD for 12 weeks in Part A.\n\nMTX was administered orally as background therapy.","id":"OG004","title":"Placebo"}],"paramType":"MEAN","populationDescription":"All randomized participants who received study drug in Parts A and B and had physician's and participant's assessments of disease activity and participant's pain evaluated at analysis time points. LOCF was used to impute missing post-baseline values.","reportingStatus":"POSTED","timeFrame":"Baseline, Weeks 12 and 24","title":"Mean Change From Baseline to Weeks 12 and 24 in Physician's Global Assessment of Disease Activity, Patient's Global Assessment of Disease Activity and Patient's Assessment of Pain","type":"SECONDARY","unitOfMeasure":"units on a scale"}